OBJECTIVE: This systematic review critically evaluated clinical practice guidelines (CPGs) for treating adults with major depressive disorder, dysthymia, or subthreshold or minor depression for recommendations following inadequate response to first-line treatment with selective serotonin reuptake inhibitors (SSRIs). METHOD: Searches for CPGs (January 2004 to November 2014) in English included 7 bibliographic databases and grey literature sources using CPG and depression as the keywords. Two raters selected CPGs on depression with a national scope. Data extraction included definitions of adequate response and recommended treatment options. Two raters assessed quality using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. RESULTS: From 46,908 citations, 3167 were screened at full text. From these 21 CPG were applicable to adults in primary care and outpatient settings. Five CPGs consider patients with dysthymia or subthreshold or minor depression. None provides recommendations for those who do not respond to first-line SSRI treatment. For adults with MDD, most CPGs do not define an "inadequate response" or provide specific suggestions regarding how to choose alternative medications when switching to an alternative antidepressant. There is variability between CPGs in recommending combination strategies. AGREE II ratings for stakeholder involvement in CPG development, editorial independence, and rigor of development are domains in which depression guidelines are often less robust. CONCLUSIONS: About half of patients with depression require second-line treatment to achieve remission. Consistency and clarity in guidelines for second-line treatment of depression are therefore important for clinicians but lacking in most current guidelines. This may reflect a paucity of primary studies upon which to base conclusions.
OBJECTIVE: This systematic review critically evaluated clinical practice guidelines (CPGs) for treating adults with major depressive disorder, dysthymia, or subthreshold or minor depression for recommendations following inadequate response to first-line treatment with selective serotonin reuptake inhibitors (SSRIs). METHOD: Searches for CPGs (January 2004 to November 2014) in English included 7 bibliographic databases and grey literature sources using CPG and depression as the keywords. Two raters selected CPGs on depression with a national scope. Data extraction included definitions of adequate response and recommended treatment options. Two raters assessed quality using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument. RESULTS: From 46,908 citations, 3167 were screened at full text. From these 21 CPG were applicable to adults in primary care and outpatient settings. Five CPGs consider patients with dysthymia or subthreshold or minor depression. None provides recommendations for those who do not respond to first-line SSRI treatment. For adults with MDD, most CPGs do not define an "inadequate response" or provide specific suggestions regarding how to choose alternative medications when switching to an alternative antidepressant. There is variability between CPGs in recommending combination strategies. AGREE II ratings for stakeholder involvement in CPG development, editorial independence, and rigor of development are domains in which depression guidelines are often less robust. CONCLUSIONS: About half of patients with depression require second-line treatment to achieve remission. Consistency and clarity in guidelines for second-line treatment of depression are therefore important for clinicians but lacking in most current guidelines. This may reflect a paucity of primary studies upon which to base conclusions.
Entities:
Keywords:
clinical practice guidelines; depression; inadequate response; systematic review
Authors: J E Barrett; J W Williams; T E Oxman; E Frank; W Katon; M Sullivan; M T Hegel; J E Cornell; A S Sengupta Journal: J Fam Pract Date: 2001-05 Impact factor: 0.493
Authors: D L Musselman; A H Miller; M R Porter; A Manatunga; F Gao; S Penna; B D Pearce; J Landry; S Glover; J S McDaniel; C B Nemeroff Journal: Am J Psychiatry Date: 2001-08 Impact factor: 18.112
Authors: Willem J Kop; John S Gottdiener; Catherine M Tangen; Linda P Fried; Mary Ann McBurnie; Jeremy Walston; Anne Newman; Calvin Hirsch; Russell P Tracy Journal: Am J Cardiol Date: 2002-02-15 Impact factor: 2.778
Authors: Charles W Hoge; Sandra E Lesikar; Ramon Guevara; Jeff Lange; John F Brundage; Charles C Engel; Stephen C Messer; David T Orman Journal: Am J Psychiatry Date: 2002-09 Impact factor: 18.112
Authors: Coen H van Gool; Gertrudis I J M Kempen; Brenda W J H Penninx; Dorly J H Deeg; Aartjan T F Beekman; Jacques T M van Eijk Journal: Age Ageing Date: 2003-01 Impact factor: 10.668
Authors: Lyane Trepanier; Andrea Reyes; Constantina Stamoulos; Sylvie Beauchamp; Christian Dagenais; Gabrielle Ciquier; Martin Drapeau Journal: Adm Policy Ment Health Date: 2021-02-12
Authors: Maia Jacobs; Melanie F Pradier; Thomas H McCoy; Roy H Perlis; Finale Doshi-Velez; Krzysztof Z Gajos Journal: Transl Psychiatry Date: 2021-02-04 Impact factor: 6.222